Mydecine Innovations Group Management

Management criteria checks 4/4

Mydecine Innovations Group's CEO is Josh Bartch, appointed in Jul 2018, has a tenure of 5.75 years. total yearly compensation is CA$444.52K, comprised of 86.2% salary and 13.8% bonuses, including company stock and options. directly owns 0.61% of the company’s shares, worth €7.75K. The average tenure of the management team and the board of directors is 3.5 years and 3.8 years respectively.

Key information

Josh Bartch

Chief executive officer

CA$444.5k

Total compensation

CEO salary percentage	86.2%
CEO tenure	5.8yrs
CEO ownership	0.6%
Management average tenure	3.5yrs
Board average tenure	3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Josh Bartch's remuneration changed compared to Mydecine Innovations Group's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2023	n/a	n/a	-CA$18m
Jun 30 2023	n/a	n/a	-CA$20m
Mar 31 2023	n/a	n/a	-CA$19m
Dec 31 2022	CA$445k	CA$383k	-CA$17m
Sep 30 2022	n/a	n/a	-CA$23m
Jun 30 2022	n/a	n/a	-CA$18m
Mar 31 2022	n/a	n/a	-CA$24m
Dec 31 2021	CA$2m	CA$346k	-CA$24m
Sep 30 2021	n/a	n/a	-CA$19m
Jun 30 2021	n/a	n/a	-CA$37m
Mar 31 2021	n/a	n/a	-CA$32m
Dec 31 2020	CA$819k	CA$153k	-CA$27m
Sep 30 2020	n/a	n/a	-CA$39m
Jun 30 2020	n/a	n/a	-CA$23m
Mar 31 2020	n/a	n/a	-CA$20m
Dec 31 2019	CA$238k	CA$238k	-CA$21m
Sep 30 2019	n/a	n/a	-CA$5m
Jun 30 2019	n/a	n/a	-CA$5m
Mar 31 2019	n/a	n/a	-CA$11m
Dec 31 2018	CA$425k	CA$302k	-CA$13m

Compensation vs Market: Josh's total compensation ($USD325.58K) is about average for companies of similar size in the German market ($USD401.52K).

Compensation vs Earnings: Josh's compensation has been consistent with company performance over the past year.

CEO

Josh Bartch (35 yo)

5.8yrs

Tenure

CA$444,518

Compensation

Mr. David Joshua Bartch, also known as Josh, serves as Chairman of the Board at Mydecine Innovations Group Inc. Mr. Bartch is Co-Founder of Mydecine Innovations Group Inc. and serves as its President, Chie...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Bartch	Co-Founder	5.8yrs	CA$444.52k	0.61% CA$ 7.7k
Robert Roscow	Co-Founder	3.9yrs	CA$455.31k	0.21% CA$ 2.6k
Damon Michaels	Co-Founder & COO	3.9yrs	CA$455.31k	0.15% CA$ 1.9k
John Ross	CFO & Corporate Secretary	1.6yrs	CA$9.20k	no data
Sanford Stein	Chief Compliance Officer & General Counsel	3.5yrs	CA$317.36k	no data
Rakesh Jetly	Chief Medical Officer	3.4yrs	CA$271.20k	no data
Morgan Kervitsky	Director of Marketing	no data	no data	no data
Michel Rudolphie	President of the European Operations	3.1yrs	no data	no data
William Cook	Interim CEO & Technical Director of Mindleap Health Inc.	2.9yrs	no data	no data

3.5yrs

Average Tenure

Experienced Management: 0NF0's management team is considered experienced (3.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
David Bartch	Co-Founder	5.8yrs	CA$444.52k	0.61% CA$ 7.7k
Robert Roscow	Co-Founder	3.3yrs	CA$455.31k	0.21% CA$ 2.6k
Anton Gomez-Escolar	Member of Medical	3.8yrs	no data	no data
Vince Polito	Member of Medical	3.8yrs	no data	no data
Denton Hoyer	Member of Medical	3.8yrs	no data	no data
Ruth Lanius	Member of Medical	no data	no data	no data
Gary Wynn	Member of Medical	no data	no data	no data
Paul Frewen	Member of Medical	no data	no data	no data
Rick Barnett	Member of Medical	no data	no data	no data
Danielle Wise	Member of Medical	no data	no data	no data
David Erritzoe	Member of Medical	3.7yrs	no data	no data
Robin Carhart-Harris	Member of Medical	3.7yrs	no data	no data

3.8yrs

Average Tenure

Experienced Board: 0NF0's board of directors are considered experienced (3.8 years average tenure).

Mydecine Innovations Group Management

Management criteria checks 4/4

Key information

Recent management updates

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc., Annual General Meeting, Apr 20, 2023

Less than half of directors are independent

Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer

Mydecine Innovations Group Announces CFO Changes

Recent updates

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Mydecine Innovations Group Inc., Annual General Meeting, Apr 20, 2023

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Pangenomic Health Inc. (CNSX:NARA) completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 4.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Less than half of directors are independent

Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering.

Pangenomic Health Inc. (CNSX:NARA) signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.

Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces CFO Changes

Mydecine Innovations Group Inc. Announces Resignation of Directors

Mydecine Files Full Patent Application Covering Myco-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Mydecine Innovations Group Inc. Announces Board Changes

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 4 million.

Mydecine Innovations Group Inc. has completed a Composite Units Offering.

First quarter 2022 earnings released: CA$1.20 loss per share (vs CA$1.25 loss in 1Q 2021)

High number of new and inexperienced directors

Mydecine Innovations Group Inc., Annual General Meeting, May 26, 2022

Full year 2021 earnings released

Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Innovations Group Inc. to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic- Assisted Psychotherapy for Patients

Mydecine Innovations Group Inc. Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

Mydecine Innovations Group Inc. Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Innovations Group Inc. announced that it expects to receive CAD 5.5 million in funding

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Third quarter 2021 earnings released: CA$0.019 loss per share (vs CA$0.11 loss in 3Q 2020)

Mydecine Innovations Group Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Second quarter 2021 earnings released: CA$0.016 loss per share (vs CA$0.046 loss in 2Q 2020)

Mydecine Provides Business Update

Mydecine Innovations Group Expands Portfolio of Novel Molecules Filing New Patent for MDMA-Like Compounds

Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Mydecine Unveils Artificial Intelligence Drug Discovery Program

Mydecine Innovations Group Discovers over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms

Health Canada Approves Expansion of Mydecine's Cultivation Capabilities for Psilocybin Producing Mushrooms

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms

First quarter 2021 earnings released: CA$0.025 loss per share (vs CA$0.006 loss in 1Q 2020)

Mydecine Innovations Group Announces Management Changes

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies Its Clinical and Commercial Supply Chain

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Chief Compliance Officer ? recently sold €783k worth of stock

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 15 million.

Mydecine Innovations Group Announces Management Changes

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors

Mydecine Innovations Group Announces the Filing of Seven Provisional Patent Applications with the United States Patent and Trademark Office

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

Mydecine Innovations Group Launches Mindleap app

Mydecine Innovations Group Inc. Announces Appointment of Rakesh Jetly as Chief Medical Officer

First half earnings released

Mydecine Innovations Group Inc. (CNSX:MYCO) completed the acquisition of NeuroPharm Inc.

NewLeaf Brands Inc. (CNSX:NLB) completed the acquisition of Mindleap Health.

New 90-day low - €0.24

Mydecine Innovations Group Inc. announced that it has received CAD 2.4 million in funding

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members